Analysis of prostate gland biopsy findings in clinics of Yekaterinburg from 2000 to 2006
https://doi.org/10.17650/1726-9776-2008-4-4-33-37
Abstract
Introduction. New facilities in the diagnosis of prostate cancer and their wide introduction into the every-day practice bring about significant changes in the epidemiology of this clinical entity.
The application of screening tests with biopsy has led to developing of heterogeneous diagnostic contingents. They are characterized by various methods of forming, by stage of disease revealed on the first level of medical aid, by demographic indices.
Objective. To evaluate the structure of the diagnostic contingents formed in the patient care institutions of Sverdlovsk region we analyzed the findings of the prostate biopsies performed.
Subjects and methods. The results of 3133 prostate biopsies carried out in five patient care institutions of Yekaterinburg for a period from 2000 to 2006 were analyzed taking into account the specificity of these institutions. All the biopsies were carried out transrectally, under the control of ultrasound.
Results. Significant differences in grouping according to the stages of newly determined cases of the disease were obtained depending on the profile of the patient care institution.
Conclusion. When evaluating the diagnosis of the prostate cancer it is necessary to take into consideration the heterogeneity of the diagnostic contingents depending on the profile of the patient care institution. The percentage of the positive biopsies findings and grouping according to the stages of newly determined cases, on the whole, may serve as epidemiologic indices.
About the Authors
K. A. Ilyin
Sverdlovsk Regional Oncologic Dispensary
Russian Federation
Russian Federation
V. O. Mager
Sverdlovsk Regional Oncologic Dispensary
Russian Federation
Russian Federation
S. E. Zavatsky
Sverdlovsk Regional Oncologic Dispensary
Russian Federation
Russian Federation
A. V. Zyryanov
Sverdlovsk Regional Clinical Hospital №1
Russian Federation
Russian Federation
I. V. Badgenov
Sverdlovsk Regional Clinical Hospital №1
Russian Federation
Russian Federation
O. V. Juravlyov
Sverdlovsk Regional Clinical Hospital №1
Russian Federation
Russian Federation
D. A. Dyeminov
Sverdlovsk Regional Clinical Hospital №1
Russian Federation
Russian Federation
Ya. V. Bershadsky
Sverdlovsk Regional Clinical Hospital №1
Russian Federation
Russian Federation
A. A. Badgenov
Sverdlovsk Regional Clinical Hospital №1
Russian Federation
Russian Federation
M. A. Frank
City Clinical Hospital №40 (Yekaterinburg)
Russian Federation
Russian Federation
R. Sh. Shamuratov
City Clinical Hospital №40 (Yekaterinburg)
Russian Federation
Russian Federation
Ye. A. Saffronova
Yekaterinburg Diagnostic Centre
Russian Federation
Russian Federation
V. B. Yakovlev
Yekaterinburg Diagnostic Centre
Russian Federation
Russian Federation
V. V. Tretyakov
Sverdlovsk Regional Hospital for War Invalids
Russian Federation
Russian Federation
A. S. Sushentsev
Sverdlovsk Regional Hospital for War Invalids
Russian Federation
Russian Federation
References
1. Матвеев Б.П. Клиническая онкоурология. М.; 2003. с. 435—44.
2. Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2005 г. Вестн РОНЦ им. Н.Н. Блохина РАМН. 2007; 18(2)(прил. 1):52—89.
3. Sakr W.A., Haas G.P., Cassin B.F. et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379—85.
4. Satariano W.A., Ragland K.E., Van Den Eeden S.K. Cause of death in men diagnosed with prostate carcinoma. Cancer 1998;83(6):1180—8.
5. Scardino P.T., Weaver R., Hudson A.L. Early detection of prostate cancer. Hum Pathol 1992; 23(3):211—22.
6. Coldman A.J., Phillips N., Pickles T.A. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ 2003;168(1):31—5.
7. Holmberg L., Bill-Axelson A., Helgesen F. et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. NEJM 2002;347(11):781—9.
8. Albertsen P.C., Hanley J.A., Fine J. 20year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293(17):2095—101.
9. Pu Y.-S., Fujimoto H., Kakizoe T., Myers R. The 18th International Symposium: controversies in prostate cancer diagnosis and treatment. Jpn J Clin Oncol 2005;35(11):680—9.
10. Johansson J.-E., Andren O., Andersson S.-O. et al. Natural history of early, localized prostate cancer. JAMA 2004;291(22):2713—9.
11. Jemal A., Ward E., Wu X. et al. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 2005;14(3):590—5.
12. Маринбах Е.Б. Рак предстательной железы. М.: Медицина; 1989.
13. Gann P.H., Hennekens C.H., Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995;273(4):289—94.
14. Keetch D.W., McMurtry J.M., Smith D.S. et al. Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol 1996;156:428—31.
15. Presti J.C. Jr., Chang J.J., Bhargava V. et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000;163(1):163—6.
16. Stewart C.S., Leibovich B.C., Weaver A.L., Lieber M.M. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001;166(1):86——91.
17. Zackrisson B., Aus G., Bergdahl S. et al. The risk of finding focal cancer (less than 3 mm) remains high on rebiopsy of patients with persistently increased prostate specific antigen but the clinical significance is guestionable. J Urol 2004;171(4):1500—3.
18. Coley C.M., Barry M.J., Mulley A.G. Clinical guideline. Part III: Screening for prostate cancer. Ann Intern Med 1997;126(6):480—4.
19. Scherr D., Swindle P.R., Scardino P.T. National comprehensive cancer network guidelines for the management of prostate cancer. Urology 2003;61(Suppl 2A):14—24.
20. Brawer M.K. Screening for prostate cancer. Semin Surg Oncol 2000;18:29—36.
21. Roehrborn C.G., NcConnell J., Bonilla J. et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol 2000;163(1):13—20.
22. Basler J.W., Thompson I.M. Lest we abandon digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst 1998;90(23):1761—3.
23. Thompson I.M., Pauler D.K., Goodman P.J. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < 4.0 ng per milliliter. N Engl J Med 2004;350(22):2239—46.
24. Graefen M., Karakiewicz P.I., Cagiannos I. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2002;20(15):3206—12.
25. Karazanashvili G., Abrahamsson P.-A. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol 2003;169(2):445—57.
26. Scott R., Mutchnik D.L., Laskowski T.Z., Schmalhorst W.R. Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J Urol 1969;101(4):602—7.
27. Вишневский А.Г. Население России 2003—2004. Одиннадцатый—двенадцатый ежегодный демографический доклад. М.: Наука; 2006.
Review
For citations:
Ilyin K.A., Mager V.O., Zavatsky S.E., Zyryanov A.V., Badgenov I.V., Juravlyov O.V., Dyeminov D.A., Bershadsky Ya.V., Badgenov A.A., Frank M.A., Shamuratov R.Sh., Saffronova Ye.A., Yakovlev V.B., Tretyakov V.V., Sushentsev A.S. Analysis of prostate gland biopsy findings in clinics of Yekaterinburg from 2000 to 2006. Cancer Urology. 2008;4(4):33-37. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-4-33-37
Views:
266
Email this article 